Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy

Lexicon Pharmaceuticals ((LXRX)) announced an update on their ongoing clinical study.

Study Overview: Lexicon Pharmaceuticals is conducting a study titled ‘A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy (SONATA-HCM)’. The study aims to assess changes in symptoms and functional limitations in patients with hypertrophic cardiomyopathy (HCM) when treated with sotagliflozin compared to a placebo. This research is significant as it seeks to provide a new treatment option for individuals suffering from this condition.

Intervention/Treatment: The study is testing the drug sotagliflozin, administered as a 400 mg oral tablet once daily. The purpose is to evaluate its effectiveness in alleviating symptoms of HCM.

Study Design: This Phase 3 interventional study uses a randomized, parallel-group design with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary goal is treatment-focused, comparing sotagliflozin to a placebo over a 26-week period.

Study Timeline: The study began on September 24, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 7, 2025, indicating ongoing progress.

Market Implications: The progress of this study could influence Lexicon Pharmaceuticals’ stock performance positively, as successful results may lead to a new marketable treatment for HCM. This could also impact investor sentiment favorably, especially if sotagliflozin proves to be a viable competitor in the cardiomyopathy treatment market.

The study is currently recruiting, with further details available on the ClinicalTrials portal.